報價延遲最少15分鐘:2025/07/20 20:19 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.8279 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.93/-1.08
|
|
企業價值
10.80M
|
| 資產負債 |
|
每股賬面淨值
0.30
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/20 20:19 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulationof cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed. |
